A new sublingual formulation of zolpidem for the treatment of sleep-onset insomnia

Expert Review of Neurotherapeutics

Volumn 12, Issue 2, 2012, Pages 141-153

  Staner, Luc ^a,b   Danjou, Philippe ^b   Luthringer, Remy ^b  

^a Centre Hospitalier de Rouffach   (France)

^b FORENAP   (France)

Author keywords

Edluar ; insomnia; sleep induction; sleep onset latency; sublingual formulation; zolpidem

Indexed keywords

4 AMINOBUTYRIC ACID; BENZODIAZEPINE; CYTOCHROME P450; DOXYLAMINE; ESZOPICLONE; FLUNITRAZEPAM; FLURAZEPAM; HYPNOTIC AGENT; INTERMEZZO; ITRACONAZOLE; RIFAMPICIN; TEMAZEPAM; TRAZODONE; TRIAZOLAM; UNCLASSIFIED DRUG; ZALEPLON; ZOLPIDEM; ZOLPIDEM TARTRATE; ZOPICLONE;

AMNESIA; AREA UNDER THE CURVE; COGNITIVE BEHAVIORAL STRESS MANAGEMENT; CONFUSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DROWSINESS; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; HALLUCINATION; HEADACHE; HUMAN; HYPNOSIS; INSOMNIA; NAUSEA; POLYSOMNOGRAPHY; REM SLEEP; REVIEW; SINGLE DRUG DOSE; SLEEP TIME; VERTIGO;

ADMINISTRATION, SUBLINGUAL; HUMANS; HYPNOTICS AND SEDATIVES; PYRIDINES; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 84856621481     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.197     Document Type: Review

References (124)

1. Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med. Rev. 6, 97-111 (2002). (Pubitemid 35231066)
2. Freeman HL. Is there a need for a para hypnotic ? Approaches to the co-diagnosis of insomnia and anxiety. J. Drug Dev. Clin. Pract. 7, 289-302 (1996).
3. Edinger JD, Fins AI, Glenn DM, et al. Insomnia and the eye of the beholder: are there clinical markers of objective sleep disturbances among adults with and without insomnia complaints? J. Consult. Clin. Psychol. 68, 586-593 (2000).
4. Katz DA, McHorney CA. Clinical correlates of insomnia in patients with chronic illness. Arch. Intern. Med. 158, 1099-1107 (1998). (Pubitemid 28242314)
5. Morin CM, Gramling SE. Sleep patterns and aging: comparison of older adults with and without insomnia complaints. Psychol. Aging 4, 290-294 (1989).
6. Johnson LC, Spinweber CL. Good and poor sleepers differ in Navy performance. Mil. Med. 148, 727-731 (1983). (Pubitemid 13024283)
7. Lautenbacher S, Kundermann B, Krieg JC. Sleep deprivation and pain perception. Sleep Med. Rev. 10, 357-369 (2006). (Pubitemid 44307712)
8. Scott JP, McNaughton LR, Polman RC. Effects of sleep deprivation and exercise on cognitive, motor performance and mood. Physiol. Behav. 87, 396-408 (2006). (Pubitemid 43188837)
9. Van Dongen HP, Maislin G, Mullington JM, Dinges DF. The cumulative cost of additional wakefulness: dose-response effects on neurobehavioral functions and sleep physiology from chronic sleep restriction and total sleep deprivation. Sleep 26, 117-126 (2003). (Pubitemid 39610686)
10. NIH. National Institutes of Health state-of-the-science conference statement: manifestations and management of chronic insomnia in adults. Sleep 28, 1049-1057 (2005).
11. Staner L. Insomnia comorbid with depression. Sleep Med. Rev. 14, 35-46 (2010).
12. Mellinger GB, Balter MB, Uhlenhuth EH. Insomnia and its treatment. Arch. Gen. Psychiatry 42, 225-232 (1985).
13. Perlis ML, Smith MT, Cacialli DO, Nowakowski S, Orff H. On the comparability of pharmacotherapy and behavior therapy for chronic insomnia: commentary and implications. J. Psychosom. Res. 54, 51-59 (2003). (Pubitemid 36168032)
14. Monti JM. Effect of zolpidem on sleep in insomniac patients. Eur. J. Clin. Pharmacol. 36, 461-466 (1989). (Pubitemid 19135208)
15. Dingemanse J, Bury D, Hussain Y, van Giesbergen P. Comparative tolerability, pharmacodynamic and pharmacokinetic of a metabolite of quinolizinone hypnotic and zolpidem in healthy subjects. Drug Metab. Dispos. 28, 1411-1416 (2000).
16. Cope DW, Wulff P, Oberto A, et al. Abolition of zolpidem sensitivity in mice with a point mutation in the GABAA receptor gamma2 subunit. Neuropharmacology 47, 17-34 (2004). (Pubitemid 38686308)
17. Cope DW, Halbsguth C, Karayannis T et al. Loss of zolpidem efficacy in the hippocampus of mice with the GABAA receptor gamma2 F77I point mutation. Eur. J. Neurosci. 21, 3002-3016 (2005). (Pubitemid 40917064)
18. Sancar F, Ericksen SS, Kucken AM, Teissére JA, Czajkowski C. Structural determinants for high-affinity zolpidem binding to GABA-A receptors. Mol. Pharmacol. 71, 38-46 (2007). (Pubitemid 46020976)
19. McKernan RM, Quirk K, Prince R, et al. GABAA receptor subtypes immunopurified from rat brain with alpha subunit-specific antibodies have unique pharmacological properties. Neuron 7, 667-676 (1991).
20. Pritchett DB, Seeburg PH. Gammaaminobutyric acid A receptor alpha 5-subunit creates novel type II benzodiazepine receptor pharmacology. J. Neurochem. 54, 1802-1804 (1990).
21. Ruano D, Vizuete M, Cano J, Machado A, Vitorica J. Heterogeneity in the allosteric interaction between the gammaaminobutyric acid (GABA) binding site and three different benzodiazepine binding sites of the GABAA/benzodiazepine receptor complex in the rat nervous system. J. Neurochem. 58, 485-493 (1992).
22. Mertens S, Benke D, Mohler H. GABAA receptor populations with novel subunit combinations and drug binding profiles identified in brain by alpha 5-and delta-subunit-specific immunopurification. J. Biol. Chem. 268, 5965-5973 (1993). (Pubitemid 23090933)
23. Maric D, Maric I, Wen X, et al. GABAA receptor subunit composition and functional properties of Cl-channels with differential sensitivity to zolpidem in embryonic rat hippocampal cells. J. Neurosci. 19, 4921-4937 (1999). (Pubitemid 29270128)
24. Crestani F, Martin JR, Möhler H, Rudolph U. Mechanism of action of the hypnotic zolpidem in vivo. Br. J. Pharmacol. 131, 1251-1254 (2000).
25. Rudolph U, Möhler H. GABA-based therapeutic approaches: GABAA receptor subtype function. Curr. Opin. Phramacol. 6, 18-23 (2006). (Pubitemid 43103815)
26. Rowlett JK, Spealman RD, Lelas S. Discriminative stimulus effects of zolpidem in squirrel monkeys: comparison with conventional benzodiazepines and sedative-hypnotics. J. Pharmacol. Exp. Ther. 291, 1233-1241 (1999).
27. Rowlett JK, Spealman RD, Lelas S, Cook JM, Yin W. Discriminative stimulus effects of zolpidem in squirrel monkeys: role of GABA(A)/alpha1 receptors. Psychopharmacology 165, 209-215 (2003). (Pubitemid 36197594)
28. Mirza NR, Rodgers RJ, Mathiasen LS. Comparative cue generalization profiles of L-838, 417, SL651498, zolpidem, CL218,872, ocinaplon, bretazenil, zopiclone, and various benzodiazepines in chlordiazepoxide and zolpidem drug discrimination. Pharmacol. Exp. Ther. 316, 1291-1299 (2006). (Pubitemid 43345305)
29. Rowlett JK, Platt DM, Lelas S, Atack JR, Dawson GR. Different GABAA receptor subtypes mediate the anxiolytic, abuserelated, and motor effects of benzodiazepine-like drugs in primates. Proc. Natl Acad. Sci. USA 102, 915-920 (2005). (Pubitemid 40282765)
30. Mirza NR, Nielsen EØ. Do subtypeselective gamma-aminobutyric acid A receptor modulators have a reduced propensity to induce physical dependence in mice? J. Pharmacol. Exp. Ther. 316, 1378-1385 (2006). (Pubitemid 43348698)
31. Blednov YA, Jung S, Alva H, et al. Deletion of the alpha1 or beta2 subunit of GABAA receptors reduces actions of alcohol and other drugs. J. Pharmacol. Exp. Ther. 304, 30-36 (2003). (Pubitemid 36008909)
32. de Almeida RM, Rowlett JK, Cook JM, Yin W, Miczek KA. GABAA/alpha1 receptor agonists and antagonists: effects on species-typical and heightened aggressive behavior after alcohol selfadministration in mice. Psychopharmacology 172, 255-263 (2004). (Pubitemid 38392317)
33. McKernan RM, Whiting PJ. Which GABAA-receptor subtypes really occur in the brain? Trends Neurosci. 19, 139-143 (1996).
34. Saper CB, Chou TC, Scammell TE. The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci. 24, 726-731 (2001). (Pubitemid 33097540)
35. Szymusiak R, McGinty D. Hypothalamic regulation of sleep and arousal. Ann. NY Acad. Sci. 1129, 275-286 (2008). (Pubitemid 351994150)
36. Haas H, Panula P. The role of histamine and the tuberomammilary nucleus in the nervous system. Nat. Rev. Neurosci. 4, 121-130 (2003). (Pubitemid 37271382)
37. Sergeeva OA, Erikson KS, Sharanova IN, Vorobjev VS, Haas HL. GABA(A) receptor heterogeneity in histaminergic neurons. Eur. J. Neurosci. 16, 1472-1482 (2002). (Pubitemid 35334984)
38. Nelson LE, Guo TZ, Lu J, Saper CB, Franks NP, Maze M. The sedative component of anaesthesia is mediated by GABA(A) receptors in endogenous sleep pathway. Nat. Neurosci. 5, 979-984 (2002).
39. Kopp C, Rudolph U, Tobler I. Sleep EEG changes after zolpidem in mice, Neuroreport 15, 2299-2302 (2004). (Pubitemid 39392259)
40. Steriade M. Brain electrical activity and sensory processing during wake and sleep states. In: Principles and Practice of Sleep Medicine, 4th Edition. Kryger MH, Roth T, Dement WC (Eds). Elsevier Sauders, Philadelphia, PA, USA, 101-119 (2005).
41. Jia F, Goldstein PA, Harrison NL. The modulation of synaptic GABAA receptors in the thalamus by eszopiclone and zolpidem. J. Pharmacol. Exp. Ther. 328, 1000-1006 (2009).
42. Holm KJ, Goa KL. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 59, 865-889 (2000). (Pubitemid 30232327)
43. Swainston Harrison T, Keating GM. Zolpidem: a review of its use in the management of insomnia. CNS Drugs 19, 65-89 (2005). (Pubitemid 40173974)
44. Thénot JP, Hermann P, Durand A. Pharmacokinetics and metabolism of zolpidem in various animal species and in man. In: Imidazopyridines In Sleep Disorders: A Novel Experimental Approach. Sauvanet JP, Langer SZ, Morselli PL (Eds). Raven Press, New York, NY, USA, 21-23 (1988).
45. Drover DR. Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone. Clin. Pharmacokinet. 43, 227-238 (2004). (Pubitemid 38429303)
46. Greenblatt DJ, Legagneux E, Harmatz JS et al. Dynamics and kinetics of a modifiedrelease formulation of zolpidem. Comparison with immediate-release standard zolpidem and placebo. J. Clin. Pharmacol. 46, 1469-1480 (2006). (Pubitemid 44704207)
47. Fraisse J, Garrigou-Gadenne D, Thénot JP. Pharmacokinetic and metabolic profiles of zolpidem. In: Zolpidem: An Update of its Pharmacological Properties and Therapeutic Place in The Management of Insomnia. Freeman H, Puech AJ, Roth T (Eds). Elsevier, Paris, France, 45-57 (1996).
48. Hesse LM, von Moltke LL, Greenblatt DJ. Clinically important drug interactions with zopiclone, zolpidem and zaleplon. CNS Drugs 17, 513-532 (2003). (Pubitemid 36693705)
49. Greenblatt DJ, Harmatz JS, von Moltke LL et al. Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences. J. Pharmacol. Exp. Ther. 293, 435-443 (2000). (Pubitemid 30244092)
50. Greenblatt DJ, Harmatz JS, von Moltke LL et al. Zolpidem pharmacokinetic properties in young females: influence of smoking and oral contraceptive use. J. Clin. Pharmacol. 42, 1142-1146 (2002).
51. Olubodun JO, Ochs HR, von Moltke LL et al. Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. Br. J. Clin. Pharmacol. 56, 297-304 (2003). (Pubitemid 37069221)
52. Monti JM, Pandi-Perumal SR, Langer SZ. Zolpidem: its use in the treatment of sleep disorder. In: Sleep Disorders, Diagnosis and Therapeutics. Pandi-Perumal SR, Verster JC, Monti JM, Lader M, Langer SZ (Eds). Informa Healthcare, London, UK, 295-323 (2008).
53. Scharf MB, Roth T, Vogel GB, Walsh JK. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J. Clin. Psychiatry 55, 192-199 (1994). (Pubitemid 24184828)
54. Monti JM, Monti D, Estévez F, Giusti M. Sleep in patients with chronic primary insomnia during long-term zolpidem administration and after its withdrawal. Int. Clin. Psychopharmacol. 11, 255-263 (1996). (Pubitemid 27049290)
55. Wheatley D. Zolpidem: a new imidazopyridine hypnotic. Psychopharmacol. Bull. 25, 124-127 (1989).
56. Dockhorn RJ, Dockhorn DW. Zolpidem in the treatment of short-term insomnia: a randomized, double blind, placebocontrolled clinical trial. Clin. Neuropharmacol. 19, 333-340 (1996). (Pubitemid 26250116)
57. Lahmeyer H, Wilcox CS, Kann J. Subjective efficacy of zolpidem in outpatients with chronic insomnia. Clin. Drug Invest. 13, 134-144 (1997).
58. Hermann WM, Dubicki S, Wober W. Zolpidem: a four week pilot polysomnographic study in patients with chronic sleep disturbances. In: Imidazopyridines in Sleep Disorders : a Novel Experimental Approach. Sauvanet JP, Langer SZ, Morselli PL (Eds). Raven Press, New York, NY, USA, 261-278 (1988).
59. De Roeck JMJ, Cluydts RJG. A polysomnographic study of short-term treatment with zolpidem in chronic psychophysiological insomnia. In: Stilnox, Proceedings of the 1st Imidazopyridine Symposium. Kurtz D, Monti JM (Eds). Adis International, New Delhi, India, 34-42 (1991).
60. Staner L, Demazières A, Luthringer R. Use of psychotropic drugs in the elderly: effects on sleep architecture. In: Principles and Practice of Geriatric Sleep Medicine. Pandi-Perumal SR, Monti J, Monjan AW (Eds). Cambridge University Press, Cambridge, UK, 371-383 (2010).
61. Uchimura N, Nakajima T, Hayash K, et al. Effect of zolpidem on sleep architecture and its next-morning residual effect in insomniac patients: a randomized cross-over comparative study with brotizolam. Prog. Neuropsychopharmacol. Biol. Psychiatry 30, 22-29 (2006). (Pubitemid 43024072)
62. Dolenc L, Vujic D, Vodušek DB, Henigsberg N, Demarin V, Kocemba J. Multicenter double-blind study of zolpidem and triazolam in treatment of chronic insomnia in elderly. Sleep 21(Suppl. 1), 135 (1998).
63. Leger D, Roger M, Gerard D. [Sleep and life rhythm in a population of elderly insomniacs]. Revue de Gériatrie 23, 73-84 (1998).
64. Walsh JK, Erman M, Erwin CW, et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSMIII-R primary insomnia. Human Psychopharmacol. 3, 191-198 (1998). (Pubitemid 28216251)
65. Schadeck B, Chelly M, Ansellem D, Cohen A, Peraudeau P, Scheck F. [Comparative efficacy of doxylamine (15 mg) and zolpidem (10 mg) in the treatment of insomnia : a placebo-controlled study]. Sem. Hop. 72, 428-439 (1996). (Pubitemid 26149881)
66. Monti JM, Attali P, Monti D, Zipfel A, de la Giclais B, Morselli PL. Zolpidem and rebound insomnia -a double-blind, controlled polysomnographic study in chronic insomniac patients. Pharmacopsychiatry 27, 166-175 (1994). (Pubitemid 24214280)
67. Ancoli-Israel S, Walsh JK, Mangano RM, Fujimori M. Zaleplon, a novel nonbenzodiazepine hypnotic effectively treats insomnia in elderly patients without causing rebound effects. Prim. Care Companion J. Clin. Psychiatry 1, 114-120 (1999).
68. Leppik I, Roth-Schecheter GB, Gray GW, Cohn MA, Owens D. Double-blind, placebo-controlled comparison of zolpidem, triazolam, and temazepam in elderly patients with insomnia. Drug Dev. Res. 40, 230-238 (1997). (Pubitemid 27334335)
69. Cluydts R, Peeters K, de Bouyalsky I, Lavoisy J. Comparison of continuous versus intermittent administration of zolpidem in chronic insomniacs: a double-blind, randomized pilot study. J. Int. Med. Res. 26, 13-24 (1998). (Pubitemid 28066176)
70. Hajak G, Cluydts R, Declerck A, et al. Continuous versus non-nightly use of zolpidem in chronic insomnia: results of a large-scale, double-blind, randomized, outpatient study. Int. Clin. Psychopharmacol. 17, 9-17 (2002). (Pubitemid 34056520)
71. Walsh JK, Roth T, Randazzo A, et al. Eight weeks of non-nightly use of zolpidem for primary insomnia. Sleep 23, 1087-1096 (2000). (Pubitemid 32046177)
72. Perlis ML, McCall WV, Krystal AD, Walsh JK. Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia. J. Clin. Psychiatry 65, 1128-1137 (2004).
73. Allain H, Arbus L, Schck S. Efficacy and safety of zolpidem administered 'as needed' in primary insomnia: results of a doubleblind, placebo-controlled study. Clin. Drug Invest. 21, 391-400 (2001). (Pubitemid 32553601)
74. Jacobs GD, Pace-Schott EF, Stickgold R, Otto MW. Cognitive behaviour therapy and pharmacotherapy for insomnia. A randomized controlled trial and direct comparison. Arch. Int. Med. 164, 1888-1896 (2004). (Pubitemid 39274359)
75. Morin CM, Vallières A, Guay B, et al. Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial. JAMA 301, 2005-2015 (2009).
76. Roth T, Hull SG, Lankford DA, Rosenberg R, Scharf MB. Low-dose sublingual zolpidem tartrate is associated with dose-related improvement in sleep onset and duration in insomnia characterized by middle-of-the-night (MOTN) awakenings. Sleep 31, 1277-1284 (2008).
77. Caille G, Spenard J, Lacasse Y. Pharmacokinetics of two lorazepam formulations, oral and sublingual, after multiple doses. Biopharm. Drug. Dipos. 4, 31-42 (1983). (Pubitemid 13147809)
78. Fuji I. Relative bioavailability of midazolam following sublingual versus oral administration in healthy volunteers. J. Pharmacobiodyn. 11, 206-209 (1988).
79. Staner L, Eriksson M, Cornette F, et al. Sublingual zolpidem is more effective than oral zolpidem in initiating early onset of sleep in the post-nap model of transient insomnia: a polysomnographic study. Sleep Med. 10, 616-620 (2008).
80. Staner C, Joly F, Jacquot N, et al. Sublingual zolpidem in early onset of sleep compared to oral zolpidem: polysomnographic study in patients with primary insomnia. Curr. Med. Res. Opin. 26, 1423-1431 (2010).
81. Palminteri R, Narbonne G. Safety profile of zolpidem. In: Imidazopyridines in Sleep Disorders: A Novel Experimental Approach. Sauvanet JP, Langer SZ, Morselli PL (Eds). Raven Press, New York, NY, USA, 351-361 (1988).
82. Pringuey D, Sallière D. Tolerability and safety of zolpidem. In: Zolpidem: An Update of its Pharmacological Properties and Therapeutic Place in The Management of Insomnia. Freeman H, Puech AJ, Roth T (Eds). Elsevier, Paris, France, 195-214 (1996).
83. Terzano MG, Milioli G, De Paolis D, Parrino L. Z-drugs: comparative tolerability. In: Sleep Disorders, Diagnosis and Therapeutics. Informa Healthcare, London, UK, 364-378 (2008).
84. Ahrens J. [Treatment of sleep disorder with zolpidem, a drug without dependence potential]. Therapiewoche Schweiz 9, 660-662 (1993). (Pubitemid 23310046)
85. Toner LC, Tsambiras BM, Catalano G, Catalano MC, Cooper DS. Central nervous system side effects associated with zolpidem treatment. Clin. Neuropharmacol. 23, 54-58 (2000). (Pubitemid 30090414)
86. Coleman DE, Ota K. Hallucinations with zolpidem and fluoxetine in an impaired driver. J. Forensic Sci. 49, 392-393 (2004). (Pubitemid 38298472)
87. Kito S, Koga Y. Visual hallucinations and amnesia associated with zolpidem triggered by fluvoxamine: a possible interaction. Int. Psychogeriatr. 18, 749-751 (2006). (Pubitemid 44623006)
88. Elko CJ, Burgess JL, Robertson WO. Zolpidem-associated hallucinations and serotonin reuptake inhibition: a possible interaction. J. Toxicol. Clin. Toxicol. 36, 195-203 (1998). (Pubitemid 28302532)
89. Dolder CR, Nelson MH. Hypnosedativeinduced complex behaviours: incidence, mechanisms and management. CNS Drugs 22, 1021-1036 (2008).
90. Bonnet MH, Arand DL. Hyperarousal and insomnia. Sleep Med. Rev. 1, 97-108 (1997). (Pubitemid 127675856)
91. Riemann D, Spiegelhalder K, Feige B, et al. The hyperarousal model of insomnia: a review of the concept and its evidence. Sleep Med. Rev. 14(1), 19-31 (2010).
92. Pigeon WR, Perlis ML. Sleep homeostasis in primary insomnia. Sleep Med. Rev. 10, 247-254 (2006). (Pubitemid 44107725)
93. Schneider-Helmert D. Twenty-four-hour sleep-wake function and personality patterns in chronic insomniacs and healthy controls. Sleep 10, 452-462 (1987).
94. Stepanski E, Zorick F, Roehrs T, Young D, Roth T. Daytime alertness in patients with chronic insomnia compared with asymptomatic control subjects. Sleep 11, 54-60 (1988).
95. Regestein QR, Dambrosia J, Hallett M, Murawski B, Paine M. Daytime alertness in patients with primary insomnia. Am. J. Psychiatry 150, 1529-1534 (1993). (Pubitemid 23289312)
96. Fleming J, Moldofsky H, Walsh JK, Scharf M, Nino MG, Radonjic D. Comparison of the residual effects and efficacy of short term zolpidem, flurazepam and placebo in patients with chronic insomnia. Clin. Drug Invest. 9, 303-313 (1995).
97. Dujardin K, Guieu JD, Leconte-Lambert C, Leconte P, Borderies P, de La Giclais B. Comparison of the effects of zolpidem and flunitrazepam on sleep structure and daytime cognitive functions. A study of untreated insomniacs. Pharmacopsychiatry 31, 14-18 (1998). (Pubitemid 28080593)
98. Staner L, Ertle S, Boeijinga P, et al. Next-day residual effects of hypnotics in DSM-IV primary insomnia: a driving simulator study with simultaneous electroencephalogram monitoring. Psychopharmacology 181, 790-798 (2005). (Pubitemid 41400765)
99. Vermeeren A, O'Hanlon JF, Declerck AC, Kho L. Acute effects of zolpidem and flunitrazepam on sleep, memory and driving performance, compared to those of partial sleep deprivation and placebo. Acta Ther. 21, 47-64 (1995).
100. Partinen M, Hirvonen K, Hublin C, Halavaara M, Hiltunen H. Effects of after-midnight intake of zolpidem and temazepam on driving ability in women with non-organic insomnia. Sleep Med. 4, 553-561 (2003). (Pubitemid 38145658)
101. Otmani S, Demazières A, Staner C, et al. Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers. Hum. Psychopharmacol. 23, 693-705 (2008).
102. Maarek L, Cramer P, Attali P, Coquelin JP, Morselli PL. The safety and efficacy of zolpidem in insomniac patients: a long-term open study in general practice. J. Int. Med. Res. 20, 162-170 (1992).
103. Schlich D, L'Heritier C, Coquelin JP, Attali P, Kryrein HJ. Long-term treatment of insomnia with zolpidem: a multicentre general practitioner study of 107 patients. J. Int. Med. Res. 19, 271-279 (1991).
104. Scharf MB, Mendels J, Thorpy M, Weiss B. Safety of long-term zolpidem treatment in patients with insomnia. Curr. Ther. Res. 55, 1100-1111 (1994). (Pubitemid 24303671)
105. Hajak G, Bandelow B, Zulley J, Pittrow D. As needed' pharmacotherapy combined with stimulus control treatment in chronic insomnia -assessment of a novel intervention strategy in a primary care setting. Ann. Clin. Psychiatry 14, 1-7 (2002). (Pubitemid 34538826)
106. Levy P, Massuel MA, Gerard DA. As-needed' prescription of zolpidem for insomnia in routine general practice. Clin. Drug Invest. 24, 625-632 (2004). (Pubitemid 39577342)
107. Soldatos CR, Dikeos DG, Whitehead A. Tolerance and rebound insomnia with rapidly eliminated hypnotics: a metaanalysis of sleep laboratory studies. Int. Clin. Psychopharmacol. 14, 287-303 (1999).
108. Dooley M, Plosker GL. Zaleplon: a review of its use in the treatment of insomnia. Drugs 60, 413-445 (2000).
109. Erman MK, Zammit G, Rubens R, et al. A polysomnographic placebo-controlled evaluation of the efficacy and safety of eszopiclone relative to placebo and zolpidem in the treatment of primary insomnia. J. Clin. Sleep Med. 4, 229-234 (2008). (Pubitemid 352039433)
110. Ware CJ, Walsh JK, Scharf MB, Roehrs T, Roth T, Vogel GW. Minimal rebound insomnia after treatment with 10-mg zolpidem. Clin. Neuropharmacol. 20, 116-125 (1997). (Pubitemid 27154838)
111. Silvestri R, Ferrillo F, Murri L, et al. Rebound insomnia after abrupt discontinuation of hypnotic treatment: double-blind randomized comparison of zolpidem versus triazolam. Hum. Psychopharmacol. 11, 225-233 (1996).
112. Oude Voshaar RC, van Balkom AJLM, Zitman FG. Zolpidem is not superior to temazepam with respect to rebound insomnia: a controlled study. Eur. Neuropsychopharmacol. 14, 301-306 (2004). (Pubitemid 38649087)
113. Roger M, Attali P, Coquelin J-P. Multicenter, double-blind, controlled comparison of zolpidem and triazolam in elderly patients with insomnia. Clin. Ther. 15, 127-136 (1993). (Pubitemid 23102363)
114. Parrino L, Smerieri A, Giglia F, Milioli G, De Paolis F, Terzano MG. Polysomnographic study of intermittent zolpidem treatment in primary sleep maintenance insomnia. Clin. Neuropharmacol. 31, 40-50 (2008). (Pubitemid 351321440)
115. Hajak G, Mller WE, Wittchen HU, Pittrow D, Kirch W. Abuse and dependence potential for the nonbenzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction 98, 1371-1378 (2003). (Pubitemid 37297243)
116. Lemoine P, Allain H, Janus C, Sutet P. Gradual withdrawal of zopiclone (7.5 mg) and zolpidem (10 mg) in insomniacs treated for at least 3 months. Eur. Psychiatry 10(Suppl. 3), 161S-165S (1995).
117. Ganzoni E, Santoni JP, Chevillard V, Sébille M, Mathy B. Zolpidem in insomnia: a 3-year post-marketing surveillance study in Switzerland. J. Int. Med. Res. 23, 61-73 (1995).
118. Hajak G, Bandelow B. Safety and tolerance of zolpidem in the treatment of disturbed sleep: a post-marketing surveillance of 16944 cases. Int. Clin. Psychopharmacol. 13, 157-167 (1998). (Pubitemid 28372339)
119. Ganzoni E, Gugger M. Safety profile of zolpidem: two studies in 3805 patients with Swiss practitioners. Schweiz. Rundsch. Med. Prax. 88, 1120-1127 (1999). (Pubitemid 29299968)
120. Danjou P, Paty I, Fruncillo R, et al. A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening. Br. J. Clin. Pharmacol. 48, 367-374 (1999). (Pubitemid 29417720)
121. Tsutsui S; Zolpidem Study Group. A double-blind comparative study of zolpidem versus zopiclone in the treatment of chronic primary insomnia. J. Int. Med. Res. 29, 163-177 (2001). (Pubitemid 32655212)
122. Kaplan JP, Georges P. Imidazol[1,2-a] pyridine derivates and their therapeutic use. European Patent: 0050563. (1989) (1982).
123. Edluar prescribing information. www.edluar.com/EDLUAR-PI.pdf
124. International Narcotics Control Board. List of psychotropic substances under international control. www.incb.org/pdf/e/list/green.pdf